These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25522951)

  • 1. Prognostic impact of neuroendocrine differentiation in high-grade serous ovarian carcinoma.
    Taube ET; Denkert C; Pietzner K; Dietel M; Sehouli J; Darb-Esfahani S
    Virchows Arch; 2015 Mar; 466(3):333-42. PubMed ID: 25522951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD56 (Neural Cell Adhesion Molecule) Expression in Ovarian Carcinomas: Association With High-Grade and Advanced Stage But Not With Neuroendocrine Differentiation.
    Bösmüller HC; Wagner P; Pham DL; Fischer AK; Greif K; Beschorner C; Sipos B; Fend F; Staebler A
    Int J Gynecol Cancer; 2017 Feb; 27(2):239-245. PubMed ID: 27984374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature.
    Hatano Y; Tamada M; Asano N; Hayasaki Y; Tomita H; Morishige KI; Hara A
    Diagn Pathol; 2019 Jan; 14(1):4. PubMed ID: 30636633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroendocrine differentiation in extrahepatic bile duct carcinomas and its prognostic significance.
    Hong SM; Kim MJ; Pi DY; Jo D; Yu E; Ro JY
    Hum Pathol; 2005 Jul; 36(7):732-40. PubMed ID: 16084941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroendocrine Marker Expression in Primary Non-neuroendocrine Epithelial Tumors of the Ovary: A Study of 551 Cases.
    Kendall Bártů M; Němejcová K; Michálková R; Bui QH; Drozenová J; Fabian P; Fadare O; Hausnerová J; Laco J; Matěj R; Méhes G; Šafanda A; Singh N; Škapa P; Špůrková Z; Stolnicu S; Švajdler M; Lax SF; McCluggage WG; Dundr P
    Int J Gynecol Pathol; 2024 Mar; 43(2):123-133. PubMed ID: 37406366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
    Cho D; Park H; Park SH; Kim K; Chung M; Moon W; Kang M; Jang K
    J Ovarian Res; 2015 Feb; 8():2. PubMed ID: 25823848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The gene copy number of c-MET has a significant impact on progression-free survival in Korean patients with ovarian carcinoma.
    Kim WY; Shim SH; Jung HY; Dong M; Kim SN; Lee SJ
    Hum Pathol; 2017 Jun; 64():98-105. PubMed ID: 28428108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycodelin in ovarian serous carcinoma: association with differentiation and survival.
    Mandelin E; Lassus H; Seppälä M; Leminen A; Gustafsson JA; Cheng G; Bützow R; Koistinen R
    Cancer Res; 2003 Oct; 63(19):6258-64. PubMed ID: 14559812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of neuroendocrine markers in non-neuroendocrine endometrial carcinomas.
    Moritz AW; Schlumbrecht MP; Nadji M; Pinto A
    Pathology; 2019 Jun; 51(4):369-374. PubMed ID: 31040050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hsp70 (HSPA1) Lysine Methylation Status as a Potential Prognostic Factor in Metastatic High-Grade Serous Carcinoma.
    Jakobsson ME; Moen A; Davidson B; Falnes PØ
    PLoS One; 2015; 10(10):e0140168. PubMed ID: 26448330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
    Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
    Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.
    Dong F; Davineni PK; Howitt BE; Beck AH
    Cancer Epidemiol Biomarkers Prev; 2016 Nov; 25(11):1511-1516. PubMed ID: 27496093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B7-H4 expression in ovarian serous carcinoma: a study of 306 cases.
    Liang L; Jiang Y; Chen JS; Niu N; Piao J; Ning J; Zu Y; Zhang J; Liu J
    Hum Pathol; 2016 Nov; 57():1-6. PubMed ID: 27349304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites.
    Maelandsmo GM; Flørenes VA; Nguyen MT; Flatmark K; Davidson B
    Tumour Biol; 2009; 30(1):15-25. PubMed ID: 19194111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic role of E-cadherin in patients with advanced serous ovarian cancer.
    Bačić B; Haller H; Mrklić I; Košta V; Čarić A; Tomić S
    Arch Gynecol Obstet; 2013 Jun; 287(6):1219-24. PubMed ID: 23269354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
    Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
    Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroendocrine features in poorly differentiated endometrioid adenocarcinomas of the endometrium.
    Tamura T; Jobo T; Watanabe J; Kanai T; Kuramoto H
    Int J Gynecol Cancer; 2006; 16(2):821-6. PubMed ID: 16681768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
    Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
    J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour.
    O'Neill CJ; McBride HA; Connolly LE; Deavers MT; Malpica A; McCluggage WG
    Histopathology; 2007 May; 50(6):773-9. PubMed ID: 17493241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer.
    Miše BP; Telesmanić VD; Tomić S; Šundov D; Čapkun V; Vrdoljak E
    Pathol Oncol Res; 2015 Apr; 21(2):347-56. PubMed ID: 25108408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.